Today, one of the primary challenges in the production of consistent quality of recombinant adeno-associated virus (rAAV) remains the fact that current analytical tools are insufficient to meet all needs, due to high variability (CV 20%–40%), low sample throughput, long turnaround times. Process development can be time-consuming, especially when the team requires many development cycles for achieving a robust and consistent comparability between the development lots.
In this webinar, we will discuss a new method for AAV titer determination using real-time monitoring that eliminates the dependecy of off-line testing and associated variability caused by sample manipulation. We will demonstrate how at-line process controls, using variable pathlength technology, can offer quick and direct total viral vector analysis, during development to enhance throughput and improve decision-making.